Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
Suenaga M, Schirripa M, Cao S, Zhang W, Cremolini C, Lonardi S, Okazaki S, Berger MD, Miyamoto Y, Soni S, Barzi A, Yamaguchi T, Loupakis F, Falcone A, Lenz HJ. Suenaga M, et al. Among authors: miyamoto y. Pharmacogenomics J. 2021 Jun;21(3):285-295. doi: 10.1038/s41397-021-00207-x. Epub 2021 Feb 4. Pharmacogenomics J. 2021. PMID: 33542444
Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.
Osumi H, Yoshio T, Chin K, Ogura M, Kumekawa Y, Suenaga M, Matsusaka S, Shinozaki E, Miyamoto Y, Morishige K, Ishiyama A, Hirasawa T, Tsuchida T, Yamamoto Y, Fujisaki J, Igarashi M, Mizunuma N. Osumi H, et al. Among authors: miyamoto y. Gastric Cancer. 2016 Apr;19(2):625-630. doi: 10.1007/s10120-015-0517-9. Epub 2015 Aug 11. Gastric Cancer. 2016. PMID: 26260873 Clinical Trial.
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ. Okazaki S, et al. Among authors: miyamoto y. Mol Cancer Ther. 2016 Jul;15(7):1740-5. doi: 10.1158/1535-7163.MCT-15-0931. Epub 2016 May 11. Mol Cancer Ther. 2016. PMID: 27196764 Free PMC article.
Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012.
Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ. Berger MD, et al. Among authors: miyamoto y. Oncotarget. 2016 Aug 16;7(33):53668-53678. doi: 10.18632/oncotarget.10696. Oncotarget. 2016. PMID: 27449091 Free PMC article.
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ. Berger MD, et al. Among authors: miyamoto y. Eur J Cancer. 2017 May;77:13-20. doi: 10.1016/j.ejca.2017.02.020. Epub 2017 Mar 26. Eur J Cancer. 2017. PMID: 28347919 Free PMC article. Clinical Trial.
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ. Schirripa M, et al. Among authors: miyamoto y. Int J Cancer. 2017 Jul 15;141(2):383-392. doi: 10.1002/ijc.30715. Epub 2017 May 10. Int J Cancer. 2017. PMID: 28369940 Free PMC article. Clinical Trial.
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ. Okazaki S, et al. Among authors: miyamoto y. Int J Cancer. 2017 Sep 15;141(6):1222-1230. doi: 10.1002/ijc.30810. Epub 2017 Jun 21. Int J Cancer. 2017. PMID: 28569041 Free PMC article.
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD, Miyamoto Y, Suenaga M, Iqubal S, Barzi A, Cremolini C, Falcone A, Battaglin F, Salvatore L, Borelli B, Helentjaris TG, Lenz HJ. Okazaki S, et al. Among authors: miyamoto y. Cancer. 2017 Nov 15;123(22):4506-4514. doi: 10.1002/cncr.30880. Epub 2017 Jul 14. Cancer. 2017. PMID: 28708932 Free PMC article.
3,481 results